LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology, Inc. (NYSE: PBYI), a development stage
biopharmaceutical company, announced that results of the Phase II
clinical trial of Puma’s investigational drug PB272 (neratinib) for the
neoadjuvant treatment of breast cancer (I-SPY2 TRIAL) will be presented
in an oral presentation at the American Association for Cancer Research
(AACR) Annual Meeting 2014, April 5-9, in San Diego, California. The
presentation entitled “Neratinib plusmore...